Back to Journals » International Journal of General Medicine » Volume 8

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib- based chemotherapy

Authors Zhao J, Wang C, Song Y, Liu Y, Fang B

Received 20 December 2013

Accepted for publication 4 February 2014

Published 12 June 2015 Volume 2015:8 Pages 211—214

DOI https://doi.org/10.2147/IJGM.S59537

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2


Junmei Zhao,* Chao Wang,* Yongping Song, Yuzhang Liu, Baijun Fang

Henan Key Lab of Experimental Haematology, Henan Institute of Haematology, Henan Tumor Hospital, Zhengzhou University, Zhengzhou, People’s Republic of China
 
*These authors contributed equally to this work

Abstract: Nine pretreated patients aged >19 years with relapsed/refractory acute lymphoblastic leukemia (ALL) were treated with a combination of bortezomib plus chemotherapy before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Eight (88.9%) patients, including two Philadelphia chromosome-positive ALL patients, achieved a complete remission. Furthermore, the evaluable patients have benefited from allo-HSCT after response to this reinduction treatment. We conclude that bortezomib-based chemotherapy was highly effective for adults with refractory/relapsed ALL before allo-HSCT. Therefore, this regimen deserves a larger series within prospective trials to confirm these results.

Keywords: acute lymphoblastic leukemia, refractory, relapsed, bortezomib

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]